EUCTR2012-002138-35-NO进行中（未招募）1 期
A phase Ib/II multi-center, open-label, dose escalation study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in patients with BRAF mutant metastatic colorectal cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 162
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Metastatic colorectal cancer
- •- Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens
- •- Life expectancy = 3 months
- •- ECOG performance status = 2
- •Other protocol-defined inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 125
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 37
排除标准
- •- Symptomatic or untreated leptomeningeal disease
- •- Symptomatic brain metastasis
- •- Patients with clinically manifested diabetes
- •- Acute or chronic pancreatitis
- •- Clinically significant cardiac disease
- •Other protocol-defined exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
Study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in BRAF mutant metastatic colorectal cancerBRAF mutant metastatic colorectal cancerMedDRA version: 18.1 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002138-35-BEArray BioPharma Inc.162
进行中（未招募）
1 期
Study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in BRAF mutant metastatic colorectal cancerEUCTR2012-002138-35-ESArray BioPharma Inc.162
进行中（未招募）
1 期
Study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in BRAF mutant metastatic colorectal cancerEUCTR2012-002138-35-NLArray BioPharma Inc.156
招募中
不适用
A phase Ib/II multi-center, open-label, dose escalation study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in patients with BRAF mutant metastatic colorectal cancer.NL-OMON47136Array Biopharma Inc.25
进行中（未招募）
1 期
Study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in BRAF mutant metastatic colorectal cancerEUCTR2012-002138-35-DEArray BioPharma Inc.162